LWAC News and Press, Locust Walk Acquisition Corp.

SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc . (eFFECTOR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today completed its business combination with Locust Walk Acquisition Corp. (NASDAQ:&...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Locust Walk Acquisition Corp. Shares Skyrocket Upon Merger Approval ” Locust Walk Acquisition Corp. (NASDAQ: LWAC) surged 150% in premarket trading aft...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Locust Walk Acquisition (NASDAQ: LWAC ) stock is rocketing higher on Wednesday following news that it can move forward with the eFFECTOR Therapeutics. Source: Shutterstock.com A special meeting of shareholders...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re halfway through the week and what better way to begin the day than with a look at the biggest pre-market stock movers for Wednesday! Source: Shutterstock But before that, consider ...

Locust Walk Acquisition (NASDAQ:LWAC) announces business combination with eFFECTOR Therapeutics (NASDAQ:TXMD). The business combination is expected to close on or about Wednesday, August 25, 2021. The combined company expects will commence trading on Nasdaq under the new tradin...

SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ: LWAC) (“LWAC” or the “Company”), a special purpose acquisition company, announced today that the Company’s stockholders have approved all proposals related to the prev...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

eFFECTOR Therapeutics is a biopharmaceutical company focused on development of selective translation regulation inhibitors (STRIs) for treating cancer. CEO Dr. Steve Worland discusses its 2 drugs in clinical trials and collaboration with Pfizer. Going public in Q3 2021 through SPA...

SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1b trial evaluating zotatifin (eFT226) a...

SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (“STRIs”) for the treatment of cancer, announced today the publication of data highlighting the role of eukaryotic translation i...